As Cancer Rates Soar in Younger People, Experts Seek Answers

Two recent reports by the American Cancer Society reveal alarming increases in numerous cancers among…

Children's Health Defense

Two recent reports by the American Cancer Society reveal alarming increases in numerous cancers among millennials and Gen Z in the U.S. While mainstream medical experts debate causes, some doctors told The Defender mRNA vaccines may be to blame for the recent emergence of aggressive cancers that often don’t respond to conventional treatments.

Cancer rates among younger generations are rising at an alarming pace, with medical professionals reporting unprecedented increases in aggressive cancers over the past few years.

A study published in the August edition of The Lancet Public Health revealed that through 2019, the incidence rates for 17 of 34 cancer types were increasing in progressively younger people in the U.S., ABC News reported on July 31.

Lead author Ahmedin Jemal, DVM, Ph.D., from the American Cancer Society (ACS) told The Washington Post that if current trends in cancer and mortality rates among Gen X and millennials continue, it “may halt or even reverse the progress that we have made in reducing cancer mortality over the past several decades.”

More recent data from the ACS’ “Cancer statistics, 2024” report — with data on cancer incidence through 2020 and mortality through 2021 — showed the trend continuing.

As of 2021, among adults under 50, colorectal cancer has become the leading cause of cancer death in men and the second-leading cause in women, despite ranking fourth for both sexes in the late 1990s.

Some researchers point to lifestyle, poverty and environmental factors as potential causes for the uptick in cancers, while others suggest the COVID-19 mRNA vaccines may be to blame for the rise in “turbo cancers.”

Meanwhile, Pfizer in December 2023 spent $43 billion for Seagan, a “cancer care” biotech company with only $2.2 billion in sales. Seagan’s already-approved drugs include those for bladder cancer, cervical cancer, breast cancer and Hodgkin lymphoma.

The acquisition expands Pfizer’s oncology portfolio to 25 approved drugs, which, by the second quarter of this year, helped the company recover from last year’s drop in COVID-19 vaccine sales when its stock lost half its value.

The cancer trend has also caught the attention of health organizations worldwide, including the World Health Organization, which in February predicted a 77% rise in new cancer cases — from 20 million cases in 2022 to over 35 million cases by 2050…